Valuation : Ionis Pharmaceuticals, Inc.

Market Cap 9.65B 8.31B 7.82B 7.14B 13.36B 911B 13.39B 92.36B 35.84B 468B 36.25B 35.46B 1,507B P/E 2026 *
-16x
P/E 2027 * -31.6x
Enterprise Value 9.55B 8.22B 7.73B 7.06B 13.21B 902B 13.25B 91.37B 35.46B 463B 35.86B 35.08B 1,490B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 6.92x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Ionis Pharmaceuticals, Inc.

1 day-0.07%
1 week-4.85%
Current month-3.76%
1 month+5.48%
3 months-22.68%
6 months-26.88%
Current year-26.57%
1 week 57.47
Extreme 57.47
61.77
1 month 54.02
Extreme 54.015
64.19
Current year 50
Extreme 50.005
86.74
1 year 50
Extreme 50.005
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Others

Chief Technology Officer

110 0.0001%
31/08/26 Others

Executive/Senior Manager

58 0.0000%
31/08/26 Others

Founder

98 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-4.85%-2.12%+43.43% 9.65B
-2.54%-2.84%-1.90%+14.52% 48.93B
-0.40%+1.03%+439.20%+499.20% 45.01B
-1.42%+2.30%+45.46%+19.36% 44.07B
-1.22%-2.31%+12.40%+71.48% 40.73B
+0.53%-1.36%+16.04%+48.23% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+22.59%+116.19% 16.5B
-1.01%+0.50%+15.83%+27.98% 14.67B
-1.65%-1.03%+77.75%+37.63% 13.77B
Average -0.83%-0.00%+69.47%+97.56% 28.46B
Weighted average by Cap. -1.00%-0.06%+91.35%+119.27%

Financials

2026 *2027 *
Net sales 913M 786M 739M 676M 1.26B 86.24B 1.27B 8.74B 3.39B 44.24B 3.43B 3.35B 143B 1.4B 1.21B 1.14B 1.04B 1.94B 132B 1.95B 13.42B 5.21B 67.95B 5.27B 5.15B 219B
Net income -585M -503M -473M -432M -809M -55.19B -811M -5.59B -2.17B -28.32B -2.19B -2.15B -91.22B -314M -270M -254M -232M -434M -29.61B -435M -3B -1.16B -15.19B -1.18B -1.15B -48.94B
Net Debt -103M -88.66M -83.42M -76.2M -143M -9.73B -143M -986M -383M -4.99B -387M -378M -16.08B 56.88M 48.95M 46.05M 42.07M 78.7M 5.37B 78.92M 544M 211M 2.76B 214M 209M 8.88B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
04/09/26 $58.09 -0.07% 2,671,092
03/09/26 $58.13 -5.22% 4,347,907
02/09/26 $61.33 +2.42% 1,845,866
01/09/26 $59.88 -0.80% 1,872,594
31/08/26 $60.36 -1.13% 2,017,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
58.09USD
Average target price
88.14USD
Spread / Average Target
+51.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock